Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apellis Pharmaceuticals Inc (NQ: APLS ) 27.74 -1.10 (-3.81%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 5,672,430 Open 28.70 Bid (Size) 27.60 (5) Ask (Size) 27.74 (5) Prev. Close 28.84 Today's Range 26.96 - 28.70 52wk Range 26.96 - 73.80 Shares Outstanding 116,457,008 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day September 25, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday September 23, 2024 Via Benzinga Performance YTD -54.72% -54.72% 1 Month -28.51% -28.51% 3 Month -23.56% -23.56% 6 Month -53.54% -53.54% 1 Year -25.31% -25.31% More News Read More What's Going With Apellis Pharmaceuticals Stock Friday? September 20, 2024 Via Benzinga Apellis Stock Hammered After Eye Drug Gets A Third European Rejection September 20, 2024 Via Investor's Business Daily Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination September 20, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals September 13, 2024 Via Benzinga Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know August 02, 2024 Via Benzinga Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Present at Upcoming Investor Conferences August 29, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 August 13, 2024 Via InvestorPlace Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases August 08, 2024 Via Benzinga Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights July 17, 2024 Via Benzinga What Analysts Are Saying About Apellis Pharmaceuticals Stock June 28, 2024 Via Benzinga Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN August 08, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results August 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts May 28, 2024 Via Benzinga Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results July 18, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting July 09, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 28, 2024 Via Benzinga Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU June 28, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA) June 10, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress May 24, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street May 14, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
